Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION (CELG)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Celgene Corporation : Celgene 1st-Quarter Net Down 4.1% Amid Increased Costs

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2013 | 02:25pm CET
   By Ben Fox Rubin 
 

Celgene Corp.'s (CELG) first-quarter profit fell 4.1% as the drug maker saw higher expenses offset stronger revenue from its Revlimid and Vidaza drugs.

The company raised its full-year guidance to a range of $5.55 to $5.65 a share in adjusted earnings from $5.50 to $5.60. It also backed its full-year product sales outlook.

Celgene has continued to post improved revenue, with its flagship blood-cancer treatment Revlimid grabbing more market share and sales of Vidaza, a blood-cancer treatment that lost patent exclusivity in May 2011, continuing to rise in the face of generic competition. The biopharmaceutical company also is expanding its core hematology franchise and building out new product lines in cancer and psoriasis as part of a strategy to achieve $12 billion in product sales by 2017.

Celgene reported a profit of $384.9 million, or 89 cents a share, down from $401.5 million, or 90 cents, a year earlier. Excluding items such as stock-based compensation, per-share earnings rose to $1.37 from $1.08.

Revenue grew 15% to $1.46 billion.

Analysts polled by Thomson Reuters had most recently forecast earnings of $1.35 a share on revenue of $1.47 billion.

Total costs and expenses rose 27%.

Revlimid sales were up 16% to $1 billion while Vidaza sales rose 10% to $204 million.

Shares closed Wednesday at $118.28 and were down 0.2% premarket. The stock has gained 51% so far this year.

Write to Ben Fox Rubin at [email protected]

Order free Annual Report for Celgene Corp.

Visit http://djnweurope.ar.wilink.com/?ticker=US1510201049 or call +44 (0)208 391 6028

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
12:55p CELGENE : Cancer Research UK Announces Drug Discovery Collaboration With Celgene..
09:13a CELGENE : and Cancer Research Technology ally on drug discovery
12/14 CELGENE : DE/ Submission of Matters to a Vote of Security Holders (form 8-K/A)
12/14 CELGENE : Launches Celgene Cancer Care Links TM to Support Cancer Healthcare Cap..
12/14 CELGENE : Long-Term Efficacy Data from the Phase III GeparSepto Study in High Ri..
12/13 JUNO THERAPEUTICS : and Celgene Corporation Release Additional Data from TRANSCE..
12/13 JUNO THERAPEUTICS : and Celgene Corporation Release Additional Data from TRANSCE..
12/13 JUNO THERAPEUTICS : Highlights Key Translational Insights with JCAR017 in Patien..
12/13 Celgene, Gilead, and Regeneron are On the Mend
12/12 CELGENE CORPORATION : and bluebird bio Announce Updated Results from Ongoing Mul..
More news
News from SeekingAlpha
12/15 UPCOMING CONVERSATION WITH AN EXPERT : Highlights In CAR-T
12/15 YOUR DAILY PHARMA SCOOP : Conatus Looks Undervalued, Teva Announces Restructurin..
12/14 AGIOS PHARMACEUTICALS : Updates To Thesis And A Look Toward 2018
12/14 YOUR DAILY PHARMA SCOOP : Right Time To Buy Regeneron, Eli Lilly Gives Guidance,..
12/13 Why Tech Still Looks So Attractive
Financials ($)
Sales 2017 12 967 M
EBIT 2017 7 286 M
Net income 2017 4 215 M
Debt 2017 4 463 M
Yield 2017 -
P/E ratio 2017 20,79
P/E ratio 2018 15,42
EV / Sales 2017 6,99x
EV / Sales 2018 5,77x
Capitalization 86 140 M
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 125 $
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chief Executive Officer & Director
Scott Andrew Smith President & Chief Operating Officer
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION-6.52%86 140
JOHNSON & JOHNSON22.95%382 722
PFIZER12.25%221 738
NOVARTIS13.09%221 731
ROCHE HOLDING LTD.3.91%212 270
MERCK AND COMPANY-4.86%153 386